Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biocept Inc BIOCQ

Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular... see more

Recent & Breaking News (GREY:BIOCQ)

Biocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco

PR Newswire August 28, 2017

Biocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements

PR Newswire August 17, 2017

Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR

PR Newswire August 14, 2017

Medical Laboratories Stocks on Investors' Radar -- DexCom, Novadaq Technologies, Biocept, and Exact Sciences

PR Newswire August 11, 2017

Investor Network: Biocept, Inc. to Host Earnings Call

Accesswire August 10, 2017

Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform

PR Newswire August 7, 2017

Biocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017

PR Newswire August 3, 2017

Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection

PR Newswire July 14, 2017

Biocept Added to the Russell Microcap Index

PR Newswire June 26, 2017

Biocept and MediNcrease Health Plans Announce Provider Agreement Expanding Access to Liquid Biopsy Testing

PR Newswire June 21, 2017

Research Reports Coverage on Healthcare Stocks -- Biocept, Varian Medical Systems, Hill-Rom, and Tivity Health

PR Newswire May 24, 2017

Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood

PR Newswire May 22, 2017

Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign

PR Newswire May 18, 2017

18 Biggest Mid-Day Losers For Friday

Benzinga.com  May 12, 2017

Biocept Reports First Quarter 2017 Financial Results

PR Newswire May 11, 2017

Investor Network: Biocept, Inc. to Host Earnings Call

Accesswire May 11, 2017

The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landmark ALCMI-009 Liquid Biopsy Clinical Trial in Lung Cancer

PR Newswire May 10, 2017

Biocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11, 2017

PR Newswire May 3, 2017

Medical Laboratories Stocks Under Scanner -- Biocept, Exact Sciences, and HTG Molecular Diagnostics

PR Newswire April 11, 2017

Biocept Announces Collaboration with the OHSU Knight Cancer Institute to Increase Clinical Adoption of Liquid Biopsy Testing and to Co-Develop Additional Assay Platform Capabilities

PR Newswire April 3, 2017